06.30.25 -- Lonza Bets The House On Biologics. What's It Mean For You?

This webinar outlines the evolving CMC regulatory landscape for protein-based drugs, from preclinical to post-market stages. Through case studies, it shows how Lonza supports clients with integrated regulatory services. Key takeaways include the value of strategic planning, adapting to varied agency expectations, and partnering with experienced CDMOs to ensure regulatory success. Click Here to learn more.

Uncover how technology is revolutionizing the detection and quantification of pulmonary fibrosis markers in whole-lung sections, offering new opportunities for clinical research.

Learn how to carry out an effective technical and quality assessment and what specific criteria to prioritize when selecting a sterile injectable CMO partner.

A properly executed virtual audit facilitates thorough qualification, condenses production timelines, enhances relationship-building, and provides early insight into a CDMO’s capability and expertise.

Our Outsourced Pharma Live speakers were adamant: You need a clear and honest assessment of what both the sponsor and CDMO need and bring to the relationship.

Review how oxygen heterogeneity, caused by pressure variations and other factors in large-scale bioreactors, can significantly impact cell growth and product yield.

By partnering with a trusted company that offers expertise in navigating the challenges of scale up, drug developers can have confidence in their ability to successfully bring their products to market.

Discover how companies can de-risk their device selection as they bring this new generation of high-volume, high-viscosity biologics to market.

Consider how a CDMO with extensive experience in protein variant characterization, CQA analytics, and patient-centric product development can ensure the safety and efficacy of your biotherapeutic.

The pre-filled syringe space is one of the fastest-growing sectors, offering greater patient safety and lower costs. But pre-filled doesn’t translate to easily filled; there are obstacles to overcome.

Once you've identified a CMO partner, how do you ensure success? The secret: planning as early as possible – while your product is still in preclinical or clinical development.

Gain insights into boosting efficiency, fostering innovation, and how integrated capabilities generate value for innovators.

Examine how a new high-speed aseptic filling line can help bring your product to market with speed and efficiency while ensuring safety and high product quality.

Explore how we’ve spent the past 60 years improving healthcare and shaping the future of injectable pharmaceuticals and where we plan to head next.

Observe how we offer a holistic approach to DP development that anticipates and prevents problems early, ensuring the result is a product that is fit for purpose.